Clinical utility of RASSF1A methylation in human malignancies

British Journal of Cancer

Volumn 113, Issue 3, 2015, Pages 372-381

  Grawenda, A M ^a   O'Neill, E ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

RAS ASSOCIATION DOMAIN FAMILY PROTEIN 1A; RASSF1 PROTEIN, HUMAN; TUMOR MARKER; TUMOR SUPPRESSOR PROTEIN;

BREAST CANCER; CANCER PATIENT; CANCER RECURRENCE; CANCER RISK; CASE CONTROL STUDY; CLINICAL FEATURE; COHORT ANALYSIS; DIGESTIVE SYSTEM CANCER; DISEASE FREE SURVIVAL; DNA METHYLATION; GENE INACTIVATION; HUMAN; INCIDENCE; LUNG CANCER; META ANALYSIS; NEOPLASM; OVERALL SURVIVAL; PHENOTYPE; PRIORITY JOURNAL; PROMOTER REGION; REVIEW; GENE SILENCING; GENETICS; NEOPLASMS; PATHOLOGY; PREDICTIVE VALUE; PROGNOSIS; TUMOR INVASION;

BIOMARKERS, TUMOR; DNA METHYLATION; GENE SILENCING; HUMANS; NEOPLASM INVASIVENESS; NEOPLASMS; PREDICTIVE VALUE OF TESTS; PROGNOSIS; TUMOR SUPPRESSOR PROTEINS;

EID: 84938414806     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/bjc.2015.221     Document Type: Review

References (110)

1. Arai Y, Honda S, Haruta M, Kasai F, Fujiwara Y, Ohshima J, Sasaki F, Nakagawara A, Horie H, Yamaoka H, Hiyama E, Kaneko Y (2010) Genome-wide analysis of allelic imbalances reveals 4q deletions as a poor prognostic factor and MDM4 amplification at 1q32.1 in hepatoblastoma. Genes Chromosomes Cancer 49: 596-609.
2. Avraham A, Uhlmann R, Shperber A, Birnbaum M, Sandbank J, Sella A, Sukumar S, Evron E (2012) Serum DNA methylation for monitoring response to neoadjuvant chemotherapy in breast cancer patients. Int J Cancer 131: E1166-E1172.
3. Bagadi SAR, Prasad CP, Kaur J, Srivastava A, Prashad R, Gupta SD, Ralhan R (2008) Clinical significance of promoter hypermethylation of RASSF1A, RARbeta2, BRCA1 and HOXA5 in breast cancers of Indian patients. Life Sci 82: 1288-1292.
4. Bayram S (2012) RASSF1A Ala133Ser polymorphism is associated with increased susceptibility to hepatocellular carcinoma in a Turkish population. Gene 498: 264-269.
5. Brock MV, Hooker CM, Ota-Machida E, Han Y, Guo M, Ames S, Glöckner S, Piantadosi S, Gabrielson E, Pridham G, Pelosky K, Belinsky Sa, Yang SC, Baylin SB, Herman JG (2008) DNA methylation markers and early recurrence in stage I lung cancer. N Engl J Med 358: 1118-1128.
6. Buckingham L, Penfield Faber L, Kim A, Liptay M, Barger C, Basu S, Fidler M, Walters K, Bonomi P, Coon J (2010) PTEN, RASSF1 and DAPK site-specific hypermethylation and outcome in surgically treated stage I and II nonsmall cell lung cancer patients. Int J Cancer 126: 1630-1639.
7. Buhmeida A, Merdad A, El-Maghrabi J, Al-Thobaiti F, Ata M, Bugis A, Syrjänen K, Abuzenadah A, Chaudhary A, Gari M, Al-Qahtani M, Dallol A (2011) RASSF1A methylation is predictive of poor prognosis in female breast cancer in a background of overall low methylation frequency. Anticancer Res 31: 2975-2981.
8. Burbee DG, Forgacs E, Zochbauer-Muller S, Shivakumar L, Fong K, Gao B, Randle D, Kondo M, Virmani A, Bader S, Sekido Y, Latif F, Milchgrub S, Toyooka S, Gazdar AF, Lerman MI, Zabarovsky E, White M, Minna JD (2001) Epigenetic inactivation of RASSF1A in lung and breast cancers and malignant phenotype suppression. J Natl Cancer Inst 93: 691-699.
9. Cao D, Chen Y, Tang Y, Peng XC, Dong H, Li LH, Cheng K, Ge J, Liu JY (2013) Loss of RASSF1A expression in colorectal cancer and its association with k-ras status. Biomed Res Int 2013: 1-8.
10. Chan K, Lai P, Mok T, Chan HL, Ding C, Yeung SW, Lo YM (2008) Quantitative analysis of circulating methylated DNA as a biomarker for hepatocellular carcinoma. Clin Chem 54: 1528-1536.
11. Chen H, Suzuki M, Nakamura Y, Ohira M, Ando S, Iida T, Nakajima T, Nakagawara A, Kimura H (2006) Aberrant methylation of RASGRF2 and RASSF1A in human non-small cell lung cancer. Oncol Rep 15: 1281-1285.
12. Cho YH, Shen J, Gammon MD, Zhang Y-J, Wang Q, Gonzalez K, Xu X, Bradshaw PT, Teitelbaum SL, Garbowski G, Hibshoosh H, Neugut AI, Chen J, Santella RM (2012) Prognostic significance of gene-specific promoter hypermethylation in breast cancer patients. Breast Cancer Res Treat 131: 197-205.
13. Dammann R, Li C, Yoon JH, Chin PL, Bates S, Pfeifer GP (2000) Epigenetic inactivation of a RAS association domain family protein from the lung tumour suppressor locus 3p21.3. Nat Genet 25: 315-319.
14. Dammann R, Schagdarsurengin U, Liu L, Otto N, Gimm O, Dralle H, Boehm BO, Pfeifer GP, Hoang-Vu C (2003) Frequent RASSF1A promoter hypermethylation and K-ras mutations in pancreatic carcinoma. Oncogene 22: 3806-3812.
15. Danielsen SA, Lind GE, Kolberg M, Høland M, Bjerkehagen B, Sundby Hall K, van den Berg E, Mertens F, Smeland S, Picci P, Lothe RA (2014) Methylated RASSF1A in malignant peripheral nerve sheath tumors identifies neurofibromatosis type 1 patients with inferior prognosis. Neuro Oncol 17(1): 63-69.
16. Daniunaite K, Jarmalaite S, Kalinauskaite N, Petroska D, Laurinavicius A, Lazutka JR, Jankevicius F (2014) Prognostic value of RASSF1 promoter methylation in prostate cancer. J Urol 192(6): 1849-1855.
17. De Fraipont F, Levallet G, Creveuil C, Bergot E, Beau-Faller M, Mounawar M, Richard N, Antoine M, Rouquette I, Favrot MC, Debieuvre D, Braun D, Westeel V, Quoix E, Brambilla E, Hainaut P, Moro-Sibilot D, Morin F, Milleron B, Zalcman G (2012) An apoptosis methylation prognostic signature for early lung cancer in the IFCT-0002 trial. Clin Cancer Res 18: 2976-2986.
18. Donninger H, Vos M, Clark G (2007) The RASSF1A tumor suppressor. J Cell Sci 120(Pt 18): 3163-3172.
19. Endoh H, Yatabe Y, Shimizu S, Tajima K, Kuwano H, Takahashi T, Mitsudomi T (2003) RASSF1A gene inactivation in non-small cell lung cancer and its clinical implication. Int J Cancer 106: 45-51.
20. Euhus DM, Bu D, Milchgrub S, Xie X-J, Bian A, Leitch AM, Lewis CM (2008) DNA methylation in benign breast epithelium in relation to age and breast cancer risk. Cancer Epidemiol Biomarkers Prev 17: 1051-1059.
21. Fendri A, Masmoudi A, Khabir A, Sellami-Boudawara T, Daoud J, Frikha M, Ghorbel A, Gargouri A, Mokdad-Gargouri R (2009) Inactivation of RASSF1A, RARb2 and DAP-kinase by promoter methylation cosrrelates with lymph node metastasis in nasopharyngeal carcinoma. Cancer Biol 8: 444-451.
22. Fiegl H, Millinger S, Mueller-holzner E, Marth C, Ensinger C, Berger A, Klocker H, Goebel G, Widschwendter M (2005) Circulating tumor-specific DNA: a marker for monitoring efficacy of adjuvant therapy in cancer patients. Cancer Res (2005) 65(4): 1141-1145.
23. Fischer JR, Ohnmacht U, Rieger N, Zemaitis M, Stoffregen C, Manegold C, Lahm H (2007) Prognostic significance of RASSF1A promoter methylation on survival of non-small cell lung cancer patients treated with gemcitabine. Lung Cancer 56: 115-123.
24. Gao B, Xie X, Huang C, Shames D, Chen T, Lewis C, Bian A, Zhang B, Olopade O, Garber J, Euhus D, Tomlinson G, Minna J (2008) RASSF1A polymorphism A133S is associated with early onset breast cancer in BRCA1/2 mutation carriers. Cancer Res 68(1): 22-25.
25. Gao T, Wang S, He B, Pan Y, Song G, Gu L, Chen L, Nie Z, Xu Y, Li R (2012) The association of RAS association domain family Protein1A (RASSF1A) methylation states and bladder cancer risk: a systematic review and meta-analysis. PLoS One 7: e48300.
26. Ge Y-Z, Xu L-W, Jia R-P, Xu Z, Feng Y-M, Wu R, Yu P, Zhao Y, Gui Z-L, Tan S-J, Song Q (2014) The association between RASSF1A promoter methylation and prostate cancer: evidence from 19 published studies. Tumour Biol 35: 3881-3890.
27. Ghosh S, Ghosh A, Maiti GP, Alam N, Roy A, Roy B, Roychoudhury S, Panda CK (2008) Alterations of 3p21.31 tumor suppressor genes in head and neck squamous cell carcinoma: correlation with progression and prognosis. Int J Cancer 123: 2594-2604.
28. Göbel G, Auer D, Gaugg I, Schneitter A, Lesche R, Müller-Holzner E, Marth C, Daxenbichler G (2011) Prognostic significance of methylated RASSF1A and PITX2 genes in blood-and bone marrow plasma of breast cancer patients. Breast Cancer Res Treat 130: 109-117.
29. Guo C, Tommasi S, Liu L, Yee JK, Dammann R, Pfeifer GP (2007) RASSF1A is part of a complex similar to the Drosophila Hippo/Salvador/Lats Tumor-Suppressor Network. Curr Biol 17: 700-705.
30. Guo W, Dong Z, Chen Z, Yang Z, Wen D, Kuang G, Guo Y, Shan B (2009) Aberrant CpG island hypermethylation of RASSF1A in gastric cardia adenocarcinoma. Cancer Invest 27: 459-465.
31. Ha YS, Jeong P, Kim JS, Kwon WA, Kim IY, Yun SJ, Kim GY, Choi YH, Moon SK, Kim W (2012) Tumorigenic and prognostic significance of RASSF1A expression in low-grade (WHO grade 1 and grade 2) nonmuscle-invasive bladder cancer. Urology 79: 1411.e1-e6.
32. Hagrass Ha, Pasha HF, Shaheen MA, Abdel Bary EH, Kassem R (2014) Methylation status and protein expression of RASSF1A in breast cancer patients. Mol Biol Rep 41: 57-65.
33. Hesson L, Bièche I, Krex D, Criniere E, Hoang-Xuan K, Maher ER, Latif F (2004) Frequent epigenetic inactivation of RASSF1A and BLU genes located within the critical 3p21.3 region in gliomas. Oncogene 23: 2408-2419.
34. Hesson LB, Cooper WN, Latif F (2007) The role of RASSF1A methylation in cancer. Dis Markers 23: 73-87.
35. Honda S, Haruta M, Sugawara W, Sasaki F, Ohira M, Matsunaga T, Yamaoka H, Horie H, Ohnuma N, Nakagawara A, Hiyama E, Todo S, Kaneko Y (2008) The methylation status of RASSF1A promoter predicts responsiveness to chemotherapy and eventual cure in hepatoblastoma patients. Int J Cancer 123: 1117-1125.
36. Honda S, Miyagi H, Suzuki H, Minato M, Haruta M, Kaneko Y, Hatanaka KC, Hiyama E, Kamijo T, Okada T, Taketomi A (2013) RASSF1A methylation indicates a poor prognosis in hepatoblastoma patients. Pediatr Surg Int 29: 1147-1152.
37. Hsu H-S, Chen T-P, Hung C-H, Wen C-K, Lin R-K, Lee H-C, Wang Y-C (2007) Characterization of a multiple epigenetic marker panel for lung cancer detection and risk assessment in plasma. Cancer 110: 2019-2026.
38. Huang K, Huang S, Chen I, Liao C, Wang H, Hsieh L (2009) Methylation of RASSF1A, RASSF2A, and HIN-1 is associated with poor outcome after radiotherapy, but not surgery, in oral squamous cell carcinoma. Clin Cancer 15: 4174-4180.
39. Huang Y, Wu W, Wu K, Xu X, Tang W (2014) Association of RASSF1A promoter methylation with lung cancer risk: a meta-analysis. Asian Pac J Cancer Prev 15: 10325-10328.
40. Jarmalaite S, Jankevicius F, Kurgonaite K, Suziedelis K, Mutanen P, Husgafvel-Pursiainen K (2008) Promoter hypermethylation in tumour suppressor genes shows association with stage, grade and invasiveness of bladder cancer. Oncology 75: 145-151.
41. Jerónimo C, Henrique R, Hoque M, Mambo E, Ribeiro FR, Varzim G, Oliveira J, Teixeira MR, Lopes C, Sidransky D (2004) A quantitative promoter methylation profile of prostate cancer. Clin Cancer 10: 8472-8478.
42. Jiang Y, Cui L, Chen W, Shen S, Ding L (2012) The prognostic role of RASSF1A promoter methylation in breast cancer: a meta-analysis of published data. PLoS One 7: e36780.
43. Jo H, Kim J, Kang G, Park N, Song Y, Kang S, Lee H (2006) Association of promoter hypermethylation of the RASSF1A gene with prognostic parameters in endometrial cancer. Clin Cancer Res 16: 205-209.
44. Jones PA, Baylin SB (2002) The fundamental role of epigenetic events in cancer. Nat Rev Genet 3: 415-428.
45. Kanzaki H, Hanafusa H, Yamamoto H (2006) Single nucleotide polymorphism at codon 133 of the RASSF1 gene is preferentially associated with human lung adenocarcinoma risk. Cancer Lett 238: 128-134.
46. Karray-Chouayekh S, Trifa F, Khabir A, Boujelbane N, Sellami-Boudawara T, Daoud J, Frikha M, Jlidi R, Gargouri A, Mokdad-Gargouri R (2010) Aberrant methylation of RASSF1A is associated with poor survival in Tunisian breast cancer patients. J Cancer Res Clin Oncol 136: 203-210.
47. Katsanis SH, Katsanis N (2013) Molecular genetic testing and the future of clinical genomics. Nat Rev Genet 14: 415-426.
48. Kawai Y, Sakano S, Okayama N, Suehiro Y, Matsuyama H, Hinoda Y (2012) Association of RASSF1A genotype and haplotype with the progression of clear cell renal cell carcinoma in Japanese patients. BJU Int 110: 1070-1075.
49. Kawai Y, Sakano S, Suehiro Y, Okada T, Korenaga Y, Hara T, Naito K, Matsuyama H, Hinoda Y (2010) Methylation level of the RASSF1A promoter is an independent prognostic factor for clear-cell renal cell carcinoma. Ann Oncol 21: 1612-1617.
50. Kawamoto K, Okino ST, Place RF, Urakami S, Hirata H, Kikuno N, Kawakami T, Tanaka Y, Pookot D, Chen Z, Majid S, Enokida H, Nakagawa M, Dahiya R (2007) Epigenetic modifications of RASSF1A gene through chromatin remodeling in prostate cancer. Clin Cancer Res 13: 2541-2548.
51. Kim D, Kim J, Ji Y, Shim Y, Kim H, Han J, Park J (2003a) Hypermethylation of RASSF1A promoter is associated with the age at starting smoking and a poor prognosis in primary non-small cell lung cancer. Cancer Res 63: 3743-3746.
52. Kim D, Kim J, Park J, Lee S, Ji Y, Kwon Y, Shim Y, Han J, Park J (2003b) Relationship of Ras association domain family 1 methylation and K-ras mutation in primary non-small cell lung cancer. Cancer Res 63: 6206-6211.
53. Kim JS, Chae Y, Ha Y-S, Kim IY, Byun SS, Yun S-J, Kim W-J (2012) Ras association domain family 1A: a promising prognostic marker in recurrent nonmuscle invasive bladder cancer. Clin Genitourin Cancer 10: 114-120.
54. Kim YT, Park J-Y, Jeon YK, Park SJ, Song JY, Kang CH, Sung SW, Kim JH (2009) Aberrant promoter CpG island hypermethylation of the adenomatosis polyposis coli gene can serve as a good prognostic factor by affecting lymph node metastasis in squamous cell carcinoma of the esophagus. Dis Esophagus 22: 143-150.
55. Ko E, Lee B, Bin, Kim Y, Lee EJ, Cho EY, Han J, Shim YM, Park J, Kim D-H (2013) Association of RASSF1A and p63 with poor recurrence-free survival in node-negative stage I-II non-small cell lung cancer. Clin Cancer Res 19: 1204-1212.
56. Kok K, Osinga J, Carritt B, Davis MB, van der Hout AH, van der Veen AY, Landsvater RM, de Leij LF, Berendsen HH, Postmus PE (1987) Deletion of a DNA sequence at the chromosomal region 3p21 in all major types of lung cancer. Nature 330: 578-581.
57. Kubo T, Yamamoto H, Ichimura K, Jida M, Hayashi T, Otani H, Tsukuda K, Sano Y, Kiura K, Toyooka S (2009) DNA methylation in small lung adenocarcinoma with bronchioloalveolar carcinoma components. Lung Cancer 65: 328-332.
58. Lee E-S, Issa J-P, Roberts DB, Williams MD, Weber RS, Kies MS, El-Naggar AK (2008) Quantitative promoter hypermethylation analysis of cancer-related genes in salivary gland carcinomas: comparison with methylation-specific PCR technique and clinical significance. Clin Cancer Res 14: 2664-2672.
59. Lee M, Kim H, Byun D, Lee S, Lee C, Kim J, Chang S, Chi S (2001) Frequent epigenetic inactivation of RASSF1A in human bladder carcinoma. Cancer Res 61: 6688-6692.
60. Lee SM, Lee WK, Kim DS, Park JY (2012) Quantitative promoter hypermethylation analysis of RASSF1A in lung cancer: comparison with methylation-specific PCR technique and clinical significance. Mol Med Rep 5: 239-244.
61. Li J, El-Naggar A, Mao L (2005) Promoter methylation of p16INK4a, RASSF1A, and DAPK is frequent in salivary adenoid cystic carcinoma. Cancer 104: 771-776.
62. Li W, Deng J, Jiang P, Zeng X, Hu S, Tang J (2012) Methylation of the RASSF1A and RARb genes as a candidate biomarker for lung cancer. Exp Ther Med 3: 1067-1071.
63. Li Y-S, Xie Q, Yang D-Y, Zheng Y (2014) Role of RASSF1A promoter methylation in the pathogenesis of hepatocellular carcinoma: a meta-analysis of 21 cohort studies. Mol Biol Rep 41: 3925-3933.
64. Liao X, Siu MK-Y, Chan KY-K, Wong ES-Y, Ngan HY-S, Chan QK-Y, Li AS-M, Khoo U-S, Cheung AN-Y (2008) Hypermethylation of RAS effector related genes and DNA methyltransferase 1 expression in endometrial carcinogenesis. Int J Cancer 123: 296-302.
65. Litovkin K, Joniau S, Lerut E, Laenen A, Gevaert O, Spahn M, Kneitz B, Isebaert S, Haustermans K, Beullens M, Van Eynde A, Bollen M (2014) Methylation of PITX2, HOXD3, RASSF1 and TDRD1 predicts biochemical recurrence in high-risk prostate cancer. J Cancer Res Clin Oncol 140(11): 1849-1861.
66. Liu L, Kron KJ, Pethe VV, Demetrashvili N, Nesbitt ME, Trachtenberg J, Ozcelik H, Fleshner NE, Briollais L, van der Kwast TH, Bapat B (2011) Association of tissue promoter methylation levels of APC, TGFb2, HOXD3 and RASSF1A with prostate cancer progression. Int J Cancer 129: 2454-2462.
67. Liu L, Yoon J-H, Dammann R, Pfeifer GP (2002) Frequent hypermethylation of the RASSF1A gene in prostate cancer. Oncogene 21: 6835-6840.
68. Liu Y, Gao W, Siegfried JM, Weissfeld JL, Luketich JD, Keohavong P (2007) Promoter methylation of RASSF1A and DAPK and mutations of K-ras, p53, and EGFR in lung tumors from smokers and never-smokers. BMC Cancer 7: 74.
69. Mao W, Li P, Zheng Q, Wang C, Ge M, Hu F, Fang X, Dong Z, Ling Z (2011) Hypermethylation-modulated downregulation of RASSF1A expression is associated with the progression of esophageal cancer. Arch Med Res 42: 182-188.
70. Maruyama R, Toyooka S, Toyooka K, Harada K, Virmani S, Zöchbauer-Müller S, Farinas A, Vakar-Lopes F, Minna J, Sagalowsky A, Czerniak B, Gazdar A (2001) Aberrant promoter methylation profile of bladder cancer and its relationship to clinicopathological features. Cancer Res 61: 8659-8663.
71. Maruyama R, Toyooka S, Toyooka K, Virmani A, Zöchbauer-Müller S, Farinas A, Minna J, McConnell J, Frenkel E, Gazdar A (2002) Aberrant promoter methylation profile of prostate cancers and its relationship to clinicopathological features. Clin Cancer 8: 514-519.
72. Mehlen P, Puisieux A (2006) Metastasis: a question of life or death. Nat Rev Cancer 6: 449-458.
73. Meng W, Huebner A, Shabsigh A, Chakravarti A, Lautenschlaeger T (2012) Combined RASSF1A and RASSF2A promoter methylation analysis as diagnostic biomarker for bladder cancer. Mol Biol Int 2012: 701814.
74. Miranda E, Destro A, Malesci A, Balladore E, Bianchi P, Baryshnikova E, Franchi G, Morenghi E, Laghi L, Gennari L, Roncalli M (2006) Genetic and epigenetic changes in primary metastatic and nonmetastatic colorectal cancer. Br J Cancer 95: 1101-1107.
75. Mitra S, Mazumder Indra D, Basu PS, Mondal RK, Roy A, Roychoudhury S, Panda CK (2012) Alterations of RASSF1A in premalignant cervical lesions: clinical and prognostic significance. Mol Carcinog 51: 723-733.
76. Montavon C, Gloss BS, Warton K, Barton Ca, Statham AL, Scurry JP, Tabor B, Nguyen TV, Qu W, Samimi G, Hacker NF, Sutherland RL, Clark SJ, O'Brien PM (2012) Prognostic and diagnostic significance of DNA methylation patterns in high grade serous ovarian cancer. Gynecol Oncol 124: 582-588.
77. Neyaz MK, Kumar RS, Hussain S, Naqvi SH, Kohaar I, Thakur N, Kashyap V, Das BC, Husain SA, Bharadwaj M (2008) Effect of aberrant promoter methylation of FHIT and RASSF1A genes on susceptibility to cervical cancer in a North Indian population. Biomarkers 13: 597-606.
78. Niklinska W (2009) Prognostic significance of DAPK and RASSF1A promoter hypermethylation in non-small cell lung cancer (NSCLC). Folia Histochem Cytobiol 47: 47-48.
79. Ohshima J, Haruta M, Fujiwara Y, Watanabe N, Arai Y, Ariga T, Okita H, Koshinaga T, Oue T, Hinotsu S, Nakadate H, Horie H, Fukuzawa M, Kaneko Y (2012) Methylation of the RASSF1A promoter is predictive of poor outcome among patients with Wilms tumor. Pediatr Blood Cancer 59: 499-505.
80. Okamoto Y, Sawaki A, Ito S, Nishida T, Takahashi T, Toyota M, Suzuki H, Shinomura Y, Takeuchi I, Shinjo K, An B, Ito H, Yamao K, Fuiji M, Murakami H, Osada H, Kataoka H, Joh T, Sekido Y, Kondo Y (2011) Aberrant DNA methylation associated with aggressiveness of gastrointestinal stromal tumour. Gut 61: 392-401.
81. Pallarés J, Velasco A, Eritja N, Santacana M, Dolcet X, Cuatrecasas M, Palomar-Asenjo V, Catasús L, Prat J, Matias-Guiu X (2008) Promoter hypermethylation and reduced expression of RASSF1A are frequent molecular alterations of endometrial carcinoma. Mod Pathol 21: 691-699.
82. Pan Z, Li J, Pan X, Chen S, Wang Z, Li F, Qu S, Shao R (2009) Methylation of the RASSF1A gene promoter in Uigur women with cervical squamous cell carcinoma. Tumori 95: 76-80.
83. Pijnenborg JMa, Dam-de Veen GC, Kisters N, Delvoux B, van Engeland M, Herman JG, Groothuis PG (2007) RASSF1A methylation and K-ras and B-raf mutations and recurrent endometrial cancer. Ann Oncol 18: 491-497.
84. Ponomaryova Aa, Rykova EY, Cherdyntseva NV, Skvortsova TE, Dobrodeev AY, Zav'yalov Aa, Bryzgalov LO, Tuzikov Sa, Vlassov VV, Laktionov PP (2013) Potentialities of aberrantly methylated circulating DNA for diagnostics and post-treatment follow-up of lung cancer patients. Lung Cancer 81: 397-403.
85. Qian ZR, Sano T, Yoshimoto K, Yamada S, Ishizuka A, Mizusawa N, Horiguchi H, Hirokawa M, Asa SL (2005) Inactivation of RASSF1A tumor suppressor gene by aberrant promoter hypermethylation in human pituitary adenomas. Lab Invest 85: 464-473.
86. Reis-Filho JS, Pusztai L (2011) Gene expression profiling in breast cancer: classification, prognostication, and prediction. Lancet 378: 1812-1823.
87. Safar A, Spencer H, Su X, Coffey M, Cooney C, Ratnasinghe L, Hutchins L, Fan C (2005) Methylation profiling of archived non-small cell lung cancer: a promising prognostic system. Clin Cancer Res 11: 4400-4405.
88. Seidel C, Bartel F, Rastetter M, Bluemke K, Wurl P, Taubert H, Dammann R (2005) Alterations of cancer-related genes in soft tissue sarcomas: hypermethylation of RASSF1A is frequently detected in leiomyosarcoma and associated with poor prognosis in sarcoma. Int J Cancer 114: 442-447.
89. Shi D-T, Han M, Gao N, Tian W, Chen W (2014) Association of RASSF1A promoter methylation with gastric cancer risk: a meta-analysis. Tumour Biol 35: 943-948.
90. Shinozaki M, Hoon D, Giuliano A, Hansen N, Wang H, Turner R, Taback B (2005) Distinct hypermethylation profile of primary breast cancer is associated with sentinel lymph node metastasis. Clin Cancer Res 11: 2156-2162.
91. Sinha R, Hussain S, Mehrotra R, Kumar RS, Kumar K, Pande P, Doval DC, Basir SF, Bharadwaj M (2013) Kras gene mutation and RASSF1A, FHIT and MGMT gene promoter hypermethylation: indicators of tumor staging and metastasis in adenocarcinomatous sporadic colorectal cancer in Indian population. PLoS One 8: e60142.
92. Stuopelyte K, Daniu¯naite K, Laurinaviciene A, Ostapenko V, Jarmalaite S (2013) High-resolution melting-based quantitative analysis of RASSF1 methylation in breast cancer. Medicina (Kaunas) 49: 78-83.
93. Stutterheim J, Ichou FA, den Ouden E, Versteeg R, Caron HN, Tytgat GaM, van der Schoot CE (2012) Methylated RASSF1a is the first specific DNA marker for minimal residual disease testing in neuroblastoma. Clin Cancer Res 18: 808-814.
94. Tanemura A, Terando A, Sim M, van Hoesel A, de Maat M, Morton D, Hoon D (2009) CpG island methylator phenotype predicts progression of malignant melanoma. Clin Cancer Res 15: 1801-1807.
95. Tomizawa Y, Kohno T, Kondo H, Otsuka A, Nishioka M, Niki T, Yamada T, Maeshima A, Yoshimura K, Saito R, Minna J, Yokota J (2002) Clinico-pathological significance of epigenetic inactivation of RASSF1A at 3p21.3 in stage I lung adenocarcinoma. Clin Cancer 8: 2362-2368.
96. Van der Weyden L, Adams DJ (2007) The Ras-association domain family (RASSF) members and their role in human tumourigenesis. Biochim Biophys Acta 1776: 58-85.
97. Wang H-L, Liu P, Zhou P-Y, Zhang Y (2014a) Promoter methylation of the RASSF1A gene may contribute to colorectal cancer susceptibility: a meta-analysis of cohort studies. Ann Hum Genet 78: 208-216.
98. Wang H-L, Zhang Y, Liu P, Zhou P-Y (2014b) Aberrant promoter methylation of RASSF1A gene may be correlated with colorectal carcinogenesis: a meta-analysis. Mol Biol Rep 41: 3991-3999.
99. Wang J, Lee J, Wang L, Liu D, Lu C (2004) Value of p16 INK4a and RASSF1A promoter hypermethylation in prognosis of patients with resectable non-small cell lung cancer. Clin Cancer 6119-6125.
100. Wang J, Wang B, Chen X, Bi J (2011) The prognostic value of RASSF1A promoter hypermethylation in non-small cell lung carcinoma: a systematic review and meta-analysis. Carcinogenesis 32: 411-416.
101. Wang S, Dorsey TH, Terunuma A, Kittles Ra, Ambs S, Kwabi-Addo B (2012) Relationship between tumor DNA methylation status and patient characteristics in African-American and European-American women with breast cancer. PLoS One 7: e37928.
102. Wang Y, Yu Z, Wang T, Zhang J, Hong L, Chen L (2007) Identification of epigenetic aberrant promoter methylation of RASSF1A in serum DNA and its clinicopathological significance in lung cancer. Lung Cancer 56: 289-294.
103. Xu J, Shetty PB, Feng W, Chenault C, Bast Jr RC, Issa JJ, Hilsenbeck SG, Yu Y (2012) Methylation of HIN-1, RASSF1A, RIL and CDH13 in breast cancer is associated with clinical characteristics, but only RASSF1A methylation is associated with outcome. BMC Cancer 12: 243.
104. Yanagawa N, Tamura G, Oizumi H, Kanauchi N, Endoh M, Sadahiro M, Motoyama T (2007) Promoter hypermethylation of RASSF1A and RUNX3 genes as an independent prognostic prediction marker in surgically resected non-small cell lung cancers. Lung Cancer 58: 131-138.
105. Yang Q, Zage P, Kagan D, Tian Y, Seshadri R, Salwen H, Liu S, Chlenski A, Cohn S (2004) Association of epigenetic inactivation of RASSF1A with poor outcome in human neuroblastoma. Clin Cancer Res 10: 8493-8500.
106. Yang X, Dai W, Kwong DL-W, Szeto CYY, Wong EH-W, Ng WT, Lee AWM, Ngan RKC, Yau CC, Tung SY, Lung ML (2014) Epigenetic markers for noninvasive early detection of nasopharyngeal carcinoma by methylation-sensitive high resolution melting. Int J Cancer 136(4): E127-E135.
107. Yao D, Shi J, Shi B, Wang N, Liu W, Zhang G, Ji M, Xu L, He N, Hou P (2012) Quantitative assessment of gene methylation and their impact on clinical outcome in gastric cancer. Clin Chim Acta 413: 787-794.
108. Yee KS, Grochola L, Hamilton G, Grawenda A, Bond EE, Taubert H, Wurl P, Bond GL, O'Neill E (2012) A RASSF1A polymorphism restricts p53/p73 activation and associates with poor survival and accelerated age of onset of soft tissue sarcoma. Cancer Res 72: 2206-2217.
109. Zhang C-Y, Zhao Y-X, Xia R-H, Han J, Wang B-S, Tian Z, Wang L-Z, Hu Y-H, Li J (2014) RASSF1A promoter hypermethylation is a strong biomarker of poor survival in patients with salivary adenoid cystic carcinoma in a Chinese population. PLoS One 9: e110159.
110. Zhou SL, Cui J, Fan ZM, Li XM, Li JL, Liu BC, Zhang DY, Liu HY, Zhao XK, Song X, Wang R, Yan ZC, Yi HX, Wang LD (2013) Polymorphism of A133S and promoter hypermethylation in Ras association domain family 1A gene (RASSF1A) is associated with risk of esophageal and gastric cardia cancers in Chinese population from high incidence area in northern China. BMC Cancer 13: 259.